A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors
Phase 2
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Locally Advanced Stage III or IV Thymic Cancer
Both
Locally Advanced Stage III or IV Thymic Cancer
Trial Information
A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors
Inclusion Criteria:
- histologically confirmed thymic carcinoma
- surgically inoperable Masaoka stage III or IV
- ECOG 0-2
- at least one measurable disease
Exclusion Criteria:
- previous myocardiac infarct history within 1 year before the enrollment.
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Complete resection rate
Outcome Time Frame:
4-8 weeks later after completion of neoadjuvant chemotherapy
Safety Issue:
No
Authority:
South Korea: Korean Food and Drug Administration
Study ID:
2007-01-040
NCT ID:
NCT01312324
Start Date:
February 2007
Completion Date:
March 2016
Related Keywords:
- Locally Advanced Stage III or IV Thymic Cancer
- neoadjuvant chemotherapy
- thymic cancer
- Thymus Neoplasms
Name | Location |
|---|
